Browse diseases

…, monitoring, and treatment needs to be established. Given that MASLD is a multisystem disease, assessing cost effectiveness should c…

…policy-statement-risk-basedFan, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020…

…n (IQR) of 12.5 (11.8–13.2) years, 423 (3.2%) participants with type 2 diabetes and 2758 (0.9%) participants without diabetes developed MALO. P…

…tension, obesity/overweight, COPD, MASLD/MASH, liver cirrhosis, hepatocellular carcinoma, cardiovascular disease, chronic kidney disease, non-liver canc…

…AFPGC. Furthermore, in this case, differentiation from ruptured hepatocellular carcinoma was difficult because the lymph node metastasis had invaded the…

…f model signatures in the context of immunotherapy treatment in hepatocellular carcinoma. This work highlights the Atlas’ utility for biological discove…

…Introduction Hepatocellular carcinoma (HCC) incidence in the UK has increased by 50% over the past de…

… an anti-PD-1 inhibitor with chemoembolization in liver-limited hepatocellular carcinoma (HCC). This study, along with the status of the field, provides…

…ection and local ablation are important curative treatments for hepatocellular carcinoma. However, the 5-year recurrence rate after ablation can reach 7…

…d While the 5-year recurrence rate in patients with early-stage hepatocellular carcinoma (HCC) is around 50-70%, conventional prediction models have mai…

… of serious complications of liver cirrhosis and progression to hepatocellular carcinoma.…

…ever, no statistically significant association was observed for pancreatic cancer (HR 1.26; 95% CI: 0.87-1.82; p=0.224). Additionally, the elevat…